KLK3 and prostate cancer: Additionally, there appeared to be variability in coding practices for PSA tests as the initial population captured had nearly 20% of prostate cancer patients for whom no PSA test was recorded, leading us to restrict the population further to only capture individuals documented to have undergone at least one PSA test.